scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0969-8051(02)00346-3 |
P698 | PubMed publication ID | 12453586 |
P2093 | author name string | Michael J Welch | |
Lynne A Jones | |||
Terry L Sharp | |||
John A Engelbach | |||
Nobuyuki Oyama | |||
Joonyoung Kim | |||
Nicole M Mercer | |||
P2860 | cites work | Cancer statistics, 2002 | Q28216788 |
Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. | Q40813713 | ||
Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging | Q43666964 | ||
FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. | Q43707212 | ||
Biological determinants of cancer progression in men with prostate cancer. | Q51090543 | ||
Uptake and retention of androgens by the rat ventral prostate and consideration of their use as site directing agents | Q67242422 | ||
Synthesis of [1-11C], [2-11C], [1-11C](2H3) and [2-11C](2H3)acetate for in vivo studies of myocardium using PET | Q73537277 | ||
Performance evaluation of the microPET P4: a PET system dedicated to animal imaging | Q74272637 | ||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | prostate cancer | Q181257 |
P304 | page(s) | 783-790 | |
P577 | publication date | 2002-11-01 | |
P1433 | published in | Nuclear Medicine and Biology | Q7067979 |
P1476 | title | MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model | |
P478 | volume | 29 |
Q44629025 | 11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET. |
Q38098441 | 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients |
Q33945133 | Challenges in clinical prostate cancer: role of imaging |
Q39512219 | Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines? |
Q48325806 | Early Response Monitoring Following Radiation Therapy by Using [18F]FDG and [11C]Acetate PET in Prostate Cancer Xenograft Model with Metabolomics Corroboration |
Q39650275 | Early response assessment in prostate carcinoma by 18F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models |
Q40275645 | Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model |
Q37352995 | FDG PET in Prostate Cancer |
Q39335098 | Hypoxia upregulates CD147 through a combined effect of HIF-1α and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors. |
Q44827523 | Is 11C-choline the most appropriate tracer for prostate cancer? Against |
Q53525226 | Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model. |
Q35904989 | Microenvironmental and cellular consequences of altered blood flow in tumours |
Q37325974 | Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. |
Q53359744 | Molecular imaging of prostate cancer. |
Q26765882 | Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring |
Q34164758 | Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. |
Q38297700 | Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. |
Q37310963 | Serially heterotransplanted human prostate tumours as an experimental model |
Q26996477 | The potential of ¹¹C-acetate PET for monitoring the Fatty acid synthesis pathway in Tumors |
Q34633685 | Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor |
Q36533822 | Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma. |
Q46804582 | [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy |
Q39698461 | [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model |
Q37085677 | [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland |